Shares of the restaurant chain began trading at HK$7.19 per share, unchanged from the offer price, before plunging 7 per cent ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

Jiangsu Hengrui Pharmaceuticals, a leading Chinese developer of novel drugs that recently received approval to go public in ...

Auntea Jenny is the latest of a string of tea companies to list in Hong Kong, just this year. Emily Tan takes a closer look at that market action.

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is aiming to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong listing, according to a regulatory filing made on Thursday.

Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO ...

This digital payment services provider is likely to get a lift from China's initiatives to boost domestic consumption.

China’s Zijin Mining Group (OTCPK:ZIJMF) (OTCPK:ZIJMY) has picked Citic Securities Co. and Morgan Stanley (MS) to lead the ...

SINGAPORE] Singapore biotech start-up Mirxes launched its initial public offering (IPO) in Hong Kong on Thursday (May 15) as ...

Chinese battery giant Contemporary Amperex Technology is planning to raise as much as US$4.0 billion in the year’s biggest ...

Xpeng Inc. is considering an initial public offering for its flying car unit, Xpeng Aeroht, according to people familiar with ...